We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo Fisher Scientific and FONAR
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: SAP SE (SAP - Free Report) , Novo Nordisk A/S (NVO - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and FONAR Corp. (FONR - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for SAP, Novo Nordisk and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including SAP SE, Novo Nordisk A/S and Thermo Fisher Scientific Inc., as well a micro-cap stock FONAR Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
SAP’s shares have outperformed the Zacks Computer - Software industry over the past year (+53.6% vs. +13.3%). The company is gaining momentum in the cloud business, especially regarding its Cloud ERP Suite and the rising adoption of the "Rise with SAP" and "Grow with SAP" solutions. Steady growth in its Cloud backlog also bodes well.
SAP remains confident in its growth trajectory and has reaffirmed its outlook, expecting cloud revenues of €21.6-€21.9 billion for 2025, up 26–28% at constant currency from €17.14 billion in 2024. Operating profit growth in the first quarter of 2025 was driven by efficiencies from the successful 2024 transformation program, aiding margins.
However, ongoing softness in the software license and services business continues to weigh on performance. In the first quarter, software license revenues declined 10% year over year, while services revenue fell 1%. Also, intense competition in the cloud space remains a concern.
Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-50.5% vs. -15.9%). The company’s failure to meet the weight-loss target with CagriSema twice gave Novo Nordisk a huge setback. Intense rivalry in the obesity sector also threatens its market share. Patent expiry and pricing pressure across the diabetes market remain a woe.
Nevertheless, Novo Nordisk’s Ozempic and Rybelsus for diabetes and Wegovy for obesity are performing well, fueled by increasing demand. Label expansions of the same in cardiovascular and other indications will likely boost sales. It has been tackling the supply constraints of Wegovy by making serious investments to ramp up production.
An oral formulation of Wegovy is currently under review by the FDA for obesity and a higher dose of the injection is under review in the EU. Novo Nordisk is also pursuing other indications, like liver fibrosis and MASH for semaglutide.
Thermo Fisher’s shares have underperformed the Zacks Medical - Instruments industry over the past year (-20.6% vs. -11%). Volatile macroeconomic uncertainties can dent the company’s operations. Also, currency woes and fierce competitive pressure add to the worry.
Nevertheless, Thermo Fisher is braving the ongoing tough economic conditions by leveraging GenAI as part of the PPI Business System, resulting in strong financial performance. The company’s growth strategy has been bolstered by several recent product launches, including Olink Reveal and Thermo Scientific Vulcan Automated Lab, among others, in the first quarter.
Thermo Fisher’s continuous efforts to prioritize its partnership with customers to drive innovation and improve patient care bode well. The Zacks analyst expects the company’s revenues to witness a 7.3% CAGR during fiscal 2025-2027. Robust solvency further instills optimism about the stock.
Shares of FONAR have gained +4.2% over the past year against the Zacks Medical - Products industry’s gain of +6.5%. This microcap company with a market capitalization of $96.71 million delivers stable, recurring revenue through long-term MRI center management contracts. Strong scan volume growth (up 3.9% for the nine months ended March 31, 2025, versus the prior year) and rising utilization support site-level productivity.
The dual-modality MRI strategy (adding high-field units to STAND-UP centers) enhances throughput and clinical utility. A strong balance sheet with $54.4 million in cash and minimal debt provides growth flexibility.
Yet, rising SG&A costs and credit reserves are compressing margins, while MRI equipment sales remain weak. Revenue growth remains flat despite record scans, reflecting limited pricing power. Heavy dependence on no-fault/PIP claims and tech disruption risk from AI-driven imaging present headwinds. The stock offers deep value but requires margin recovery and tech reinvestment for re-rating.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo Fisher Scientific and FONAR
For Immediate Release
Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: SAP SE (SAP - Free Report) , Novo Nordisk A/S (NVO - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and FONAR Corp. (FONR - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for SAP, Novo Nordisk and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including SAP SE, Novo Nordisk A/S and Thermo Fisher Scientific Inc., as well a micro-cap stock FONAR Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Shrug Off Trade Deadline, FOMC Minutes Out Today
Today's Featured Research Reports
SAP’s shares have outperformed the Zacks Computer - Software industry over the past year (+53.6% vs. +13.3%). The company is gaining momentum in the cloud business, especially regarding its Cloud ERP Suite and the rising adoption of the "Rise with SAP" and "Grow with SAP" solutions. Steady growth in its Cloud backlog also bodes well.
SAP remains confident in its growth trajectory and has reaffirmed its outlook, expecting cloud revenues of €21.6-€21.9 billion for 2025, up 26–28% at constant currency from €17.14 billion in 2024. Operating profit growth in the first quarter of 2025 was driven by efficiencies from the successful 2024 transformation program, aiding margins.
However, ongoing softness in the software license and services business continues to weigh on performance. In the first quarter, software license revenues declined 10% year over year, while services revenue fell 1%. Also, intense competition in the cloud space remains a concern.
(You can read the full research report on SAP here >>>)
Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-50.5% vs. -15.9%). The company’s failure to meet the weight-loss target with CagriSema twice gave Novo Nordisk a huge setback. Intense rivalry in the obesity sector also threatens its market share. Patent expiry and pricing pressure across the diabetes market remain a woe.
Nevertheless, Novo Nordisk’s Ozempic and Rybelsus for diabetes and Wegovy for obesity are performing well, fueled by increasing demand. Label expansions of the same in cardiovascular and other indications will likely boost sales. It has been tackling the supply constraints of Wegovy by making serious investments to ramp up production.
An oral formulation of Wegovy is currently under review by the FDA for obesity and a higher dose of the injection is under review in the EU. Novo Nordisk is also pursuing other indications, like liver fibrosis and MASH for semaglutide.
(You can read the full research report on Novo Nordisk here >>>)
Thermo Fisher’s shares have underperformed the Zacks Medical - Instruments industry over the past year (-20.6% vs. -11%). Volatile macroeconomic uncertainties can dent the company’s operations. Also, currency woes and fierce competitive pressure add to the worry.
Nevertheless, Thermo Fisher is braving the ongoing tough economic conditions by leveraging GenAI as part of the PPI Business System, resulting in strong financial performance. The company’s growth strategy has been bolstered by several recent product launches, including Olink Reveal and Thermo Scientific Vulcan Automated Lab, among others, in the first quarter.
Thermo Fisher’s continuous efforts to prioritize its partnership with customers to drive innovation and improve patient care bode well. The Zacks analyst expects the company’s revenues to witness a 7.3% CAGR during fiscal 2025-2027. Robust solvency further instills optimism about the stock.
(You can read the full research report on Thermo Fisher here >>>)
Shares of FONAR have gained +4.2% over the past year against the Zacks Medical - Products industry’s gain of +6.5%. This microcap company with a market capitalization of $96.71 million delivers stable, recurring revenue through long-term MRI center management contracts. Strong scan volume growth (up 3.9% for the nine months ended March 31, 2025, versus the prior year) and rising utilization support site-level productivity.
The dual-modality MRI strategy (adding high-field units to STAND-UP centers) enhances throughput and clinical utility. A strong balance sheet with $54.4 million in cash and minimal debt provides growth flexibility.
Yet, rising SG&A costs and credit reserves are compressing margins, while MRI equipment sales remain weak. Revenue growth remains flat despite record scans, reflecting limited pricing power. Heavy dependence on no-fault/PIP claims and tech disruption risk from AI-driven imaging present headwinds. The stock offers deep value but requires margin recovery and tech reinvestment for re-rating.
(You can read the full research report on FONAR here >>>)
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.